<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828385</url>
  </required_header>
  <id_info>
    <org_study_id>PAGF-01M</org_study_id>
    <nct_id>NCT01828385</nct_id>
  </id_info>
  <brief_title>Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex</brief_title>
  <official_title>Effect of Magnesium Sulfate on the Reversal of Neuromuscular Blockade With Sugammadex: a Prospective, Randomized Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Federal de Bonsucesso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the recovery time of moderate neuromuscular blockade
      with sugammadex in adults pretreated with magnesium sulfate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sugammadex is a novel neuromuscular blocking reversal agent. Its mechanism of action is the
      encapsulation of rocuronium and vecuronium molecules. Numerous studies show a potential role
      of magnesium in reducing anesthetic requirements, sympathetic response to surgical trauma,
      antinociceptive action and neuroprotective effects. However, its use is limited because
      magnesium potentiates non-depolarizing neuromuscular blocking agents.

      Primary outcome: evaluate the effect of pretreatment with magnesium sulfate on the time
      reversal with sugammadex (recovery of the T4/T1 ratio = 0.9) of moderate neuromuscular
      blockade (two answers to a train-of-four TOF) induced by rocuronium.

      Secondary outcome: evaluate severe respiratory events, the incidence of residual
      neuromuscular blockade in the post anesthesia recovery room and postoperative pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery time of moderate neuromuscular blockade with sugammadex in adults pretreated with magnesium sulfate</measure>
    <time_frame>3 hours</time_frame>
    <description>When T1 reached 25%, a single bolus dose of sugammadex 2 mg.kg-1 was administered to facilitate the recovery. The times to reach a TOF ratio of 0.9 and T1 height value were measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess severe respiratory events, the incidence of residual neuromuscular blockade in anesthesia recovery room</measure>
    <time_frame>4 hours</time_frame>
    <description>Clinical tests and contraction of the adductor pollicis muscle in response to ulnar nerve train-of-four (TOF) stimulation was acceleromyographically quantified using a TOF-Watch SX.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group Mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Magnesium sulfate + rocuronium + sugammadex</description>
    <arm_group_label>Group Mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline + rocuronium + sugammadex</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  ASA physical status 1 or 2

          -  weight BMI 18.5-24.9

          -  otorhinolaryngological surgeries

        Exclusion Criteria:

          -  major surgery associated with massive blood loss or fluid replacement

          -  any known allergy to magnesium sulphate or any other study drugs

          -  pregnant

          -  anatomical malformations expected to result in a difficult intubation;

          -  known or suspected neuromuscular disorders and/or significant hepatic or renal
             dysfunction

          -  administration of any medication known to interfere with neuromuscular blocking agents
             (such as anticonvulsants, aminoglycosides, calcium channel blockers and magnesium
             containing medications)

          -  hypomagnesemia, hypermagnesemia, hypocalcemia, hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo A Germano Filho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Federal de Bonsucesso</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Núbia V Figueiredo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ismar L Cavalcanti, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Federal de Bonsucesso</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Herroeder S, Schönherr ME, De Hert SG, Hollmann MW. Magnesium--essentials for anesthesiologists. Anesthesiology. 2011 Apr;114(4):971-93. doi: 10.1097/ALN.0b013e318210483d. Review.</citation>
    <PMID>21364460</PMID>
  </reference>
  <reference>
    <citation>Sauer M, Stahn A, Soltesz S, Noeldge-Schomburg G, Mencke T. The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomised, prospective, placebo-controlled trial. Eur J Anaesthesiol. 2011 Dec;28(12):842-8. doi: 10.1097/EJA.0b013e328345cd11.</citation>
    <PMID>21455074</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>January 17, 2015</last_update_submitted>
  <last_update_submitted_qc>January 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Paulo Alipio Germano Filho</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Rocuronium</keyword>
  <keyword>Sugammadex sodium</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Neuromuscular block, antagonism</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

